

# Antoinette Moran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3685901/publications.pdf>

Version: 2024-02-01

91  
papers

8,804  
citations

57681

46  
h-index

49824

91  
g-index

91  
all docs

91  
docs citations

91  
times ranked

7263  
citing authors

#	ARTICLE	IF	CITATIONS
1	New Concepts in the Pathogenesis of Cystic Fibrosis-Related Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1503-1509.	1.8	14
2	Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3273-e3280.	1.8	3
3	Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial. Annals of the American Thoracic Society, 2021, 18, 75-83.	1.5	32
4	Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. Journal of Cystic Fibrosis, 2021, 20, 333-338.	0.3	40
5	Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine, 2021, 13, .	5.8	142
6	Early Impairment of Insulin Sensitivity, $\beta$ -Cell Responsiveness, and Insulin Clearance in Youth with Stage 1 Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2660-2669.	1.8	8
7	Telemedicine in cystic fibrosis. Journal of Clinical and Translational Endocrinology, 2021, 26, 100270.	1.0	5
8	IL-6 receptor blockade does not slow $\beta$ cell loss in new-onset type 1 diabetes. JCI Insight, 2021, 6, .	2.3	25
9	Cystic fibrosis related diabetes (CFRD) prognosis. Journal of Clinical and Translational Endocrinology, 2021, 26, 100278.	1.0	4
10	Institutional Factors Associated With Burnout Among Assistant Professors. Teaching and Learning in Medicine, 2020, 32, 61-70.	1.3	27
11	Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis. Journal of Cystic Fibrosis, 2020, 19, 139-145.	0.3	58
12	Continuous glucose monitoring assessment of metabolic control in east African children and young adults with type 1 diabetes: A pilot and feasibility study. Endocrinology, Diabetes and Metabolism, 2020, 3, e00135.	1.0	6
13	Cystic fibrosis related diabetes: Medical management. Journal of Cystic Fibrosis, 2019, 18, S10-S18.	0.3	27
14	Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. Journal of Cystic Fibrosis, 2019, 18, S3-S9.	0.3	85
15	Continuous glucose monitoring in cystic fibrosis - A practical guide. Journal of Cystic Fibrosis, 2019, 18, S25-S31.	0.3	35
16	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 603-613.	13.9	584
17	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.3	80
18	Cystic fibrosis related diabetes: Nutrition and growth considerations. Journal of Cystic Fibrosis, 2019, 18, S32-S37.	0.3	28

#	ARTICLE	IF	CITATIONS
19	Hypoglycemia in cystic fibrosis: Prevalence, impact and treatment. <i>Journal of Cystic Fibrosis</i> , 2019, 18, S19-S24.	0.3	13
20	Pharmacological management of cystic fibrosis related diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 185-191.	1.3	13
21	Cystic-fibrosis-related diabetes: time for oral drugs?. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 85-87.	5.5	6
22	Caregiving for children with type 1 diabetes and clinical outcomes in central India: The IDREAM study. <i>Pediatric Diabetes</i> , 2018, 19, 527-533.	1.2	12
23	A picture-based carbohydrate-counting resource for Somalis. <i>Journal of International Medical Research</i> , 2018, 46, 219-224.	0.4	3
24	An Increase in Chromogranin A-Positive, Hormone-Negative Endocrine Cells in Pancreas in Cystic Fibrosis. <i>Journal of the Endocrine Society</i> , 2018, 2, 1058-1066.	0.1	8
25	A novel triple-tracer approach to assess postprandial protein turnover. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E469-E477.	1.8	4
26	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves $\beta$ -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1917-1925.	4.3	114
27	ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2018, 19, 64-74.	1.2	119
28	Is insulin diluted when stored in water?. <i>Pediatric Diabetes</i> , 2017, 18, 237-240.	1.2	2
29	Predominance of DR3 in Somali children with type 1 diabetes in the twin cities, Minnesota. <i>Pediatric Diabetes</i> , 2017, 18, 136-142.	1.2	11
30	Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?. <i>Diabetes Care</i> , 2017, 40, 698-701.	4.3	67
31	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. <i>Diabetes Care</i> , 2017, 40, 1494-1499.	4.3	28
32	CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017, 52, S37-S43.	1.0	43
33	Increased Effector Memory Insulin-Specific CD4+ T Cells Correlate With Insulin Autoantibodies in Patients With Recent-Onset Type 1 Diabetes. <i>Diabetes</i> , 2017, 66, 3051-3060.	0.3	38
34	The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4596-4603.	1.8	20
35	Childhood diabetes in Africa. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 306-311.	1.2	34
36	Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2-year results of a randomised trial. <i>Diabetologia</i> , 2016, 59, 1153-1161.	2.9	72

#	ARTICLE	IF	CITATIONS
37	Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 974-980.	2.5	77
38	Two case reports of retained steel insulin pump infusion set needles. <i>Pediatric Diabetes</i> , 2016, 17, 160-163.	1.2	14
39	Early Alterations in Glycemic Control and Pancreatic Endocrine Function in Nondiabetic Patients With Chronic Pancreatitis. <i>Pancreas</i> , 2016, 45, 565-571.	0.5	28
40	Relation of Cardiometabolic Risk Factors between Parents and Children. <i>Journal of Pediatrics</i> , 2015, 167, 1049-1056.e2.	0.9	12
41	Childhood Wrist Circumference Is Not a Predictor of Insulin Resistance in Adulthood. <i>Journal of Pediatrics</i> , 2015, 166, 1085-1087.	0.9	8
42	Diabetes-related Mortality in Adults with Cystic Fibrosis. Role of Genotype and Sex. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 194-200.	2.5	140
43	Physical Activity, Fitness, and Cardiometabolic Risk Factors in Adult Survivors of Childhood Cancer with a History of Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1278-1283.	2.0	43
44	Age at Menarche and Cardiometabolic Risk in Adulthood: The Coronary Artery Risk Development in Young Adults Study. <i>Journal of Pediatrics</i> , 2015, 167, 344-352.e1.	0.9	64
45	Management of cystic fibrosis-related diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2014, 15, 65-76.	1.2	95
46	B-Lymphocyte Depletion With Rituximab and $\hat{I}^2$ -Cell Function: Two-Year Results. <i>Diabetes Care</i> , 2014, 37, 453-459.	4.3	210
47	Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment. <i>Diabetes Care</i> , 2014, 37, 1069-1075.	4.3	168
48	Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. <i>Pediatric Diabetes</i> , 2013, 14, 295-298.	1.2	19
49	Relation Between Serum Free Fatty Acids and Adiposity, Insulin Resistance, and Cardiovascular Risk Factors From Adolescence to Adulthood. <i>Diabetes</i> , 2013, 62, 3163-3169.	0.3	86
50	Targeting of memory T cells with alefacept in new-onset type 1 diabetes (TIDAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 284-294.	5.5	169
51	Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 306-316.	5.5	120
52	Update on cystic fibrosis-related diabetes. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 318-331.	0.3	160
53	New insights into cystic fibrosis-related diabetes in children. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 52-58.	5.5	57
54	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. <i>Lancet</i> , 2013, 381, 1905-1915.	6.3	301

#	ARTICLE	IF	CITATIONS
55	Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. <i>Pediatric Diabetes</i> , 2013, 14, 417-421.	1.2	164
56	No Relation Between Cystic Fibrosis-Related Diabetes and Type 1 Diabetes Autoimmunity. <i>Diabetes Care</i> , 2012, 35, e57-e57.	4.3	26
57	Improved glycemic control and acute complications among children with type 1 diabetes mellitus in Moshi, Tanzania. <i>Pediatric Diabetes</i> , 2012, 14, n/a-n/a.	1.2	15
58	Association of Osteocalcin With Obesity, Insulin Resistance, and Cardiovascular Risk Factors in Young Adults. <i>Obesity</i> , 2012, 20, 2194-2201.	1.5	47
59	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2011, 378, 412-419.	6.3	493
60	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. <i>Lancet, The</i> , 2011, 378, 319-327.	6.3	325
61	Predicting cardiovascular risk in young adulthood from the metabolic syndrome, its component risk factors, and a cluster score in childhood. <i>Pediatric Obesity</i> , 2011, 6, e283-e289.	3.2	88
62	Recent trends in cystic fibrosis-related diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 335-341.	1.2	40
63	Update on cystic fibrosis-related diabetes. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 611-615.	1.2	29
64	Oral glucose tolerance testing in children with cystic fibrosis. <i>Pediatric Diabetes</i> , 2010, 11, 487-492.	1.2	93
65	Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis-Related Diabetes. <i>Diabetes Care</i> , 2010, 33, 2677-2683.	4.3	213
66	Impaired Fasting Glucose in Cystic Fibrosis. <i>Diabetes Care</i> , 2010, 33, 2660-2664.	4.3	33
67	Clinical Care Guidelines for Cystic Fibrosis-Related Diabetes. <i>Diabetes Care</i> , 2010, 33, 2697-2708.	4.3	582
68	Insulin Therapy to Improve BMI in Cystic Fibrosis-Related Diabetes Without Fasting Hyperglycemia. <i>Diabetes Care</i> , 2009, 32, 1783-1788.	4.3	206
69	Management of cystic fibrosis-related diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2009, 10, 43-50.	1.2	63
70	Cystic Fibrosis-Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality. <i>Diabetes Care</i> , 2009, 32, 1626-1631.	4.3	510
71	Relation of blood pressure and body mass index during childhood to cardiovascular risk factor levels in young adults. <i>Journal of Hypertension</i> , 2009, 27, 1766-1774.	0.3	78
72	The C677T Methylene tetrahydrofolate Reductase Polymorphism and Insulin Resistance in Childhood Cancer Survivors. <i>Blood</i> , 2009, 114, 1400-1400.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Management of cystic fibrosis-related diabetes. <i>Pediatric Diabetes</i> , 2008, 9, 338-344.	1.2	72
74	Glargine versus NPH insulin in cystic fibrosis related diabetes. <i>Journal of Cystic Fibrosis</i> , 2008, 7, 134-136.	0.3	31
75	Changes in Insulin Resistance and Cardiovascular Risk During Adolescence. <i>Circulation</i> , 2008, 117, 2361-2368.	1.6	196
76	Metabolic complications of obesity in childhood and adolescence: more than just diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 21-29.	1.2	140
77	Microvascular Complications in Cystic Fibrosis-Related Diabetes. <i>Diabetes Care</i> , 2007, 30, 1056-1061.	4.3	165
78	Relation of C-Reactive Protein to Insulin Resistance and Cardiovascular Risk Factors in Youth. <i>Diabetes Care</i> , 2005, 28, 1763-1768.	4.3	78
79	Relation of Body Mass Index and Insulin Resistance to Cardiovascular Risk Factors, Inflammatory Factors, and Oxidative Stress During Adolescence. <i>Circulation</i> , 2005, 111, 1985-1991.	1.6	207
80	Diabetes Is Associated With Dramatically Decreased Survival in Female but Not Male Subjects With Cystic Fibrosis. <i>Diabetes Care</i> , 2005, 28, 2141-2144.	4.3	181
81	Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1467-1472.	1.5	24
82	Association between the Insulin Resistance of Puberty and the Insulin-Like Growth Factor-I/Growth Hormone Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4817-4820.	1.8	172
83	Relation of insulin resistance to blood pressure in childhood. <i>Journal of Hypertension</i> , 2002, 20, 509-517.	0.3	57
84	Abnormal lipid concentrations in cystic fibrosis. <i>American Journal of Clinical Nutrition</i> , 2002, 75, 1005-1011.	2.2	94
85	Diagnosis, screening, and management of cystic fibrosis-related diabetes. <i>Current Diabetes Reports</i> , 2002, 2, 111-115.	1.7	29
86	Endocrine complications of cystic fibrosis. <i>Adolescent Medicine</i> , 2002, 13, 145-59, vii-viii.	0.3	12
87	Insulin resistance syndrome in childhood: Associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. <i>Journal of Pediatrics</i> , 2001, 139, 700-707.	0.9	186
88	Protein Metabolism in Clinically Stable Adult Cystic Fibrosis Patients With Abnormal Glucose Tolerance. <i>Diabetes</i> , 2001, 50, 1336-1343.	0.3	70
89	Trends in Pulmonary Function in Patients with Cystic Fibrosis Correlate with the Degree of Glucose Intolerance at Baseline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 891-895.	2.5	317
90	Abnormal glucose metabolism in cystic fibrosis. <i>Journal of Pediatrics</i> , 1998, 133, 10-17.	0.9	162

#	ARTICLE	IF	CITATIONS
91	Glycemic Response to Dietary Supplements in Cystic Fibrosis is Dependent on the Carbohydrate Content of the Formula. <i>Journal of Parenteral and Enteral Nutrition</i> , 1996, 20, 182-186.	1.3	24